Tabalumab
タバルマブ（遺伝子組換え)
Tabalumab (Genetical Recombination)
[1143503-67-6]
Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies.[1][2] Tabalumab was developed by Eli Lilly and Company.
A phase III clinical trial for rheumatoid arthritis was halted in Feb 2013.[3] In September 2014, a second phase III trial focussing on treating systemic lupus erythematosus, was terminated early as the study failed to meet its primary endpoint.[4]
References
- 1 “Statement On A Nonproprietary Name Adopted By The USAN Council: Tabalumab” (PDF). American Medical Association.
- 2 http://www.lillyoncologypipeline.com/Pages/baff-antibody.aspx
- 3http://lilly.mediaroom.com/index.php?s=9042&item=136985
- 4http://www.genengnews.com/gen-news-highlights/lilly-halts-tabalumab-development-for-lupus/81250423/
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | BAFF |
| Identifiers | |
| CAS Number | 1143503-67-6  |
| ATC code | none |
| ChemSpider | none |
| Chemical data | |
| Formula | C6518H10008N1724O2032S38 |
| Molar mass | 146.25 kg/mol |
////////////タバルマブ , 遺伝子組換え, Tabalumab, 1143503-67-6, antibody, Monoclonal antibody
